Abstracts tagged "anti-TNF therapy"

Abstract Number: 2134 • 2014 ACR/ARHP Annual Meeting
Baseline Scintigraphic Detection of TNFá As a Predictor of Therapy Response after Treatment with Certolizumab Pegol in Rheumatoid Arthritis and Spondyloarthritis Patients
Philippe Carron¹, Bieke Lambert², Filip De Vos³, Gust Verbruggen¹, Dirk Elewaut¹ and Filip van Den Bosch¹, ¹Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²Department of Nuclear Medicine Ghent University Hospital, Department of Nuclear Medicine Ghent University Hospital, Ghent, Belgium, ³Radiopharmacy, Department of Radiopharmacy Ghent University, Ghent, Belgium
Background/Purpose: A major challenge in the biologic era is to predict clinical response. A large variability in the level of TNFα expression has been recognized…
Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Layla Saliba¹, Guillaume Moulis², Malak Aboutaam³, Grégory Pugnet², Vanessa Rousseau¹, Leila Chebane¹, Nadine Petitpain⁴, Bernadette Baldin⁵, Jean-Louis Montastruc¹ and Haleh Bagheri¹, ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, ²Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, ⁴Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, ⁵Nice University Hospital, Pharmacovigilance Regional Center, Nice, France
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…
Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting
Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?
Charlotte Mabille¹, Adeline Ruyssen Witrand², Thomas Barnetche^3,4, Arnaud Constantin⁵ and Alain G. Cantagrel⁵, ¹Rheumatology Unit, hopital Purpan, Toulouse, France, ²Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ³rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁴Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁵Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…
Abstract Number: 2440 • 2013 ACR/ARHP Annual Meeting
Is There a Role For Etoricoxib In Patients With Axial Ankylosing spondylitis Refractory To Traditional NSAID?
Maria García Manrique¹, Pilar Font², Joan Calvet³, María Cruz Fernandez⁴, Carlos Montilla⁵, Luis Linares⁶, Elia Brito⁷, Xavier Juanola⁸, Juan Mulero⁹, Rubén Queiro¹⁰, Rosa M. Morla¹¹, Rosario Garcia-Vicuña¹², Alba Erra¹³, Mireia Moreno¹⁴, Marta Larrosa¹⁵, Eduardo Collantes¹⁶ and Jordi Gratacos¹⁷, ¹Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ²Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ³Rheumatology, Corporació Sanitària Parc Taulí, Sabadell, Spain, ⁴Rheumatology, Hospital General de Móstoles, Mostoles, Spain, ⁵Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, ⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁷Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ⁸Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ⁹Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ¹⁰Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ¹¹Rheumatology, Hospital Sta Tecla, Tarragona, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³Hospital de Sant Rafael, Barcelona, Spain, ¹⁴Rheumatology, Hospital Universitari Parc Taulí, Sabadell, Spain, ¹⁵Rheumatology, Hospital Universitari Parc Tauli, Sabadell, Spain, ¹⁶Rheumatology, Hospital Reina Sofia, Cordoba, Spain, ¹⁷Rheumatology Service, Hospital Universitari Parc Taulí, Sabadell (Barcelona), Spain
Background/Purpose: Anti-TNF treatment has demonstrated its effectiveness in axial ankylosing spondylitis (AS) patients with inadecuate response to traditional NSAIDs (tNSAIDs) therapy (>=2 tNSAIDs), but also aspects…
Abstract Number: 1556 • 2013 ACR/ARHP Annual Meeting
Paradoxical Psoriasis: Experience Of a Biological Therapy Monographic Unit
Maria Luz Garcia Vivar¹, Silvia Perez Barrio², EVA Galindez Agirregoikoa³, Catalina Gomez Arango⁴, Jose Francisco Garcia Llorente⁵, Rosa Izu Belloso⁶, Esther Ruiz Lucea⁵, Ignacio Torre Salaberri⁷ and Jesus Maria Careaga Alzaga⁸, ¹RHEUMATOLOGY, Rheumatology department, Basurto University Hospital., BILBAO, Spain, ²DERMATOLOGY, Dermatology Department.Basurto University Hospital., BILBAO, Spain, ³RHEUMATOLOGY, Rheumatology Department. Basurto University Hospital., BILBAO, Spain, ⁴Rheumatology, Hospital Universitario Basurto, Bilbao, Spain, ⁵RHEUMATOLOGY, Rheumatology department. Basurto University Hospital., BILBAO, Spain, ⁶DERMATOLOGY, Dermatology Department. Basurto University Hospital. Bilbao, BILBAO, Spain, ⁷Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁸DERMATOLOGY, Dermatology department. Basurto University Hospital., BILBAO, Spain
Background/Purpose: Anti TNF therapy’s efficacy in controlling cutaneous psoriasis has widely been proven, but development of paradoxical psoriasis (PPs) as a side effect can occur.…
Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Hsin-Hua Chen^1,2, Der-Yuan Chen¹, Chao-Hsiung Tang³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Nicole Huang⁵, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²nstitute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ³Taipei Medical University, Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…
Abstract Number: 2380 • 2013 ACR/ARHP Annual Meeting
Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?
Yoon-Kyoung Sung^1,2, Soo-Kyung Cho^1,2, Soyoung Won³, Jeeseon Shim³, Dam Kim⁴, Ji-Young Choi¹, Chan-Nam Son⁵, Chan-Bum Choi⁴, Tae-Hwan Kim⁶, Jae-Bum Jun⁶, Dae-Hyun Yoo⁶ and Sang-Cheol Bae^1,2, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁵Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for…
Abstract Number: 1529 • 2013 ACR/ARHP Annual Meeting
Patients With Imaging Abnormalities Of The Sacroiliac Joints Are More Likely To Respond To TNF Alpha Inhibitors In Early Axial Spondyloarthritis. Data From The DESIR Cohort
Anna Moltó¹, Simon Paternotte², Pascal Claudepierre³ and Maxime Dougados⁴, ¹Cochin Hospital, Paris- Descartes University, Paris, France, ²Rheumatology Department, Paris- Descartes University, Cochin hospital, Paris, France, ³Rheumatology, Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, ⁴Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose: Efficacy of TNF alpha inhibitors (TNFi) has been clearly established in patients with axial SpondyloArthritis (ax-SpA), but its effectiveness and adherence with regard to…
Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting
Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling
Jason Ptacek¹, Rachael Hawtin², Brent Louie¹, Erik Evensen¹, James Cordeiro¹, Barbara Mittleman¹, Michelle Atallah¹, Alessandra Cesano², Clifton O. Bingham III³, Stacey Cofield⁴, Jeffrey R. Curtis⁵, Maria I. Danila⁴, Richard A. Furie⁶, MC Genovese⁷, Marc C. Levesque⁸, Larry W. Moreland⁸, Peter A. Nigrovic⁹, James R. O'Dell¹⁰, William H. Robinson¹¹, Nancy A. Shadick⁹, E. William St Clair¹², Christopher C. Striebich¹³, Geoffrey M Thiele¹⁴, Peter K. Gregersen⁶ and S. Louis Bridges Jr.⁴, ¹Nodality, Inc., South San Francisco, CA, ²Nodality Inc., South San Francisco, CA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁷Stanford University, Palo Alto, CA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital/Harvard University, Cambridge, MA, ¹⁰Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹¹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials. Single cell…
Abstract Number: 2362 • 2013 ACR/ARHP Annual Meeting
Incidence Of Adverse Events In Patients With Rheumatoid Arthritis and Spondyloarthritis Exposed To Anti-TNF Therapy. Data From The Brazilian Registry For Monitoring Of Biologic Therapies In Rheumatic Diseases (BiobadaBrasil)
Roberto Ranza¹, David C Titton², Valeria Vallim³, Ines Silveira⁴, Aline Ranzolin⁵, Andre Hayata⁶, Mirhelen M. Abreu⁷, Paulo Louzada-Jr⁸, Angela LBP Duarte⁵, Claiton Brenol⁹, Geraldo C Pinheiro¹⁰, Glaucio R Castro¹¹, Hellen M Carvalho¹², Isaias Costa¹³, Jose C Macieira¹⁴, Jose R Miranda¹⁵, Julio CM Bertacini¹⁶, Luis SG Barbosa¹⁷, Manoel B Bertolo¹⁸, Marcelo M. Pinheiro¹², Maria F Sauma¹⁹, Marilia B Silva²⁰, Marlene Freire²¹, Roberto A Toledo²² and Vander Fernandes²³, ¹Universidade Federal de Uberlandia, Uberlandia MG, Brazil, ²Hospital de Clínicas da UFPR, Curitiba PR, Brazil, ³Universidade Federal do Espirito Santo, Vitoria ES, Brazil, ⁴PUCRS, Porto Alegre RS, Brazil, ⁵Universidade Federal de Pernambuco, Recife PE, Brazil, ⁶CRO Osasco, Osasco SP, Brazil, ⁷Universidade Federal de São Carlos, São Carlos SP, Brazil, ⁸USP RP, Ribeirão Preto SP, Brazil, ⁹Universidade Federal do Rio Grande do Sul, Porto Alegre RS, Brazil, ¹⁰UERJ, Rio de Janeiro RJ, Brazil, ¹¹Hospital Governador Celso Ramos, Florianopolis SC, Brazil, ¹²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, ¹³Universidade Federal MS, Campo Grande MS, Brazil, ¹⁴UFS Aracaju, Aracaju SE, Brazil, ¹⁵Artrocenter Clinica Medica, Taubate SP, Brazil, ¹⁶USP SP CDMAC, São Paulo SP, Brazil, ¹⁷Universidade Federal Mato Grosso, Cuiabá MT, Brazil, ¹⁸UNICAMP, Campinas SP, Brazil, ¹⁹UFPA, Belem PA, Brazil, ²⁰Hospital Universitario Evangelico, Curitiba PR, Brazil, ²¹UFTM, Uberaba MG, Brazil, ²²FUNFARP, São José do Rio Preto SP, Brazil, ²³Universidade de Cuiabá, Cuiaba MT, Brazil
Background/Purpose: The safety profile of a-TNF biologic drugs might have substantial regional differences due to geographic and socio economic factors and to epidemiology of infectious…
Abstract Number: 1532 • 2013 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Fator Therapy Is Associated With Resolution Of Erosion In The Sacroiliac Joints Of Patients With Spondyloarthritis
Susanne Juhl Pedersen¹, Stephanie Wichuk², Praveena Chiowchanwisawakit³, Robert GW Lambert⁴ and Walter P. Maksymowych², ¹Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Medicine, University of Alberta, Edmonton, AB, Canada, ³Mahidol University, Bangkok, Thailand, ⁴Radiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Radiography of the sacroiliac joints (SIJ) in spondyloarthritis (SpA) is a valuable diagnostic tool but is unreliable and unresponsive for assessment of treatment effects.…
Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W.J. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
Abstract Number: 2339 • 2013 ACR/ARHP Annual Meeting
Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect®) For Treatment Of Rheumatoid Arthritis
H Schulze-Koops¹, R Giacomelli², W Samborski³, S Rednic⁴, M Herold⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹University of Munich, Munich, Germany, ²Università degli Studi dell'Aquila, L'Aquila, Italy, ³Ortopedyczno-Rehabilitacyjny Szpital Kliniczny, Wielkopolskie, Poland, ⁴University of Medicine & Pharmacy, Cluj-Napoca, Romania, ⁵Internal Medicine VI, Medical University of Innsbruck, Innsbruck, Austria, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional…
Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saedis Saevarsdottir¹, Michele Santacatterina², Leszek Stawiarz³, Carl Turesson⁴, Helena Forsblad⁵, Lennart T.H. Jacobsson⁶ and Staffan Lindblad⁷, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Daniel Furst¹, Mei Liu², Jeffrey D. Greenberg³ and Joel M. Kremer⁴, ¹Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ²CORRONA, Inc, Southborough, MA, ³NYU Hospital for Joint Diseases, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].